Showing results (231-240 of 305) with videos related to

Sort By:
Pageof 31
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trialsMattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Blood|December 8, 2009
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 studyAntonio Palumbo, Sara Bringhen, Benedetto Bruno, et al.
Haematologica|July 11, 2019
HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemiaValentina Griggio, Candida Vitale, Maria Todaro, et al.
Blood Cancer Journal|June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trialStefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
Pageof 31